[{"from": "human", "value": "Provide a brief overview of this molecule. [C][C][C][S][=Branch1][C][=O][=Branch1][C][=O][C][C][N][Ring1][Branch2][/N][=C][/C][=C][C][=C][Branch1][Ring2][O][Ring1][Branch1][N+1][=Branch1][C][=O][O-1]"}, {"from": "gpt", "value": "The molecule is a vector-transmitted disease affecting animals and humans in the Americas. It is commonly known as American Trypanosomiasis.  The CDC estimates that approximately 8 million people in Central America, South America, and Mexico are infected with T. cruzi, without symptoms. If Chagas disease is left untreated, life-threatening sequelae may result.  Nifurtimox, developed by Bayer, is a nitrofuran antiprotozoal drug used in the treatment of Chagas disease. On August 6 2020, accelerated FDA approval was granted for its use in pediatric patients in response to promising results from phase III clinical trials. Continued approval will be contingent upon confirmatory data. A convenient feature of Bayer's formulation is the ability to divide the scored tablets manually without the need for pill-cutting devices."}]